Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes

Author(s): Krishna A. Gajjar* and Anuradha K. Gajjar

Volume 17, Issue 2, 2020

Page: [233 - 247] Pages: 15

DOI: 10.2174/1570163815666181008165822

Price: $65

Abstract

Background: Pharmacophore mapping and molecular docking can be synergistically integrated to improve the drug design and discovery process. A rational strategy, combiphore approach, derived from the combined study of Structure and Ligand based pharmacophore has been described to identify novel GPR40 modulators.

Methods: DISCOtech module from Discovery studio was used for the generation of the Structure and Ligand based pharmacophore models which gave hydrophobic aromatic, ring aromatic and negative ionizable as essential pharmacophoric features. The generated models were validated by screening active and inactive datasets, GH scoring and ROC curve analysis. The best model was exposed as a 3D query to screen the hits from databases like GLASS (GPCR-Ligand Association), GPCR SARfari and Mini-Maybridge. Various filters were applied to retrieve the hit molecules having good drug-like properties. A known protein structure of hGPR40 (pdb: 4PHU) having TAK-875 as ligand complex was used to perform the molecular docking studies; using SYBYL-X 1.2 software.

Results and Conclusion: Clustering both the models gave RMSD of 0.89. Therefore, the present approach explored the maximum features by combining both ligand and structure based pharmacophore models. A common structural motif as identified in combiphore for GPR40 modulation consists of the para-substituted phenyl propionic acid scaffold. Therefore, the combiphore approach, whereby maximum structural information (from both ligand and biological protein) is explored, gives maximum insights into the plausible protein-ligand interactions and provides potential lead candidates as exemplified in this study.

Keywords: Pharmacophore, GPR40, diabetes, virtual scfreening, molecular docking, ligand.

Graphical Abstract

[1]
Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2015; 17(7): 675-81.
[http://dx.doi.org/10.1111/dom.12467] [PMID: 25787200]
[2]
Lu H, Fei H, Yang F, et al. Discovery of novel orally bioavailable GPR40 agonists. Bioorg Med Chem Lett 2013; 23(10): 2920-4.
[http://dx.doi.org/10.1016/j.bmcl.2013.03.060] [PMID: 23582779]
[3]
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J 2014; 7(1): 45-8.
[http://dx.doi.org/10.4066/AMJ.2014.1979] [PMID: 24567766]
[4]
Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett 2014; 24(14): 2991-3000.
[http://dx.doi.org/10.1016/j.bmcl.2014.05.019] [PMID: 24881568]
[5]
Zahanich I, Kondratov I, Naumchyk V, et al. Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40). Bioorg Med Chem Lett 2015; 25(16): 3105-11.
[http://dx.doi.org/10.1016/j.bmcl.2015.06.018] [PMID: 26096679]
[6]
Lu S. Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: a combined QM/MM study and pharmacophore modeling. Journal of Molecular Graphics and Modelling 2011; 04
[http://dx.doi.org/10.1016/j.jmgm.2011.01.006]
[7]
Niu Miaomiao, Wang Ke, Zhang Congying, et al. Poly(ADPribose) polymerase (PARP)-based pharmacophore model development and its application in designing antitumor inhibitors Journal of the Taiwan Institute of Chemical Engineers 2015.
[8]
Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, Hudson BD. Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol 2015; 172(13): 3254-65.
[http://dx.doi.org/10.1111/bph.12879] [PMID: 25131623]
[9]
Takano R, Yoshida M, Inoue M, et al. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558. Bioorg Med Chem 2015; 23(17): 5546-65.
[http://dx.doi.org/10.1016/j.bmc.2015.07.028] [PMID: 26234904]
[10]
Cooke RM, Brown AJ, Marshall FH, Mason JS. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov Today 2015; 20(11): 1355-64.
[http://dx.doi.org/10.1016/j.drudis.2015.08.003] [PMID: 26303408]
[11]
Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
[http://dx.doi.org/10.3389/fendo.2014.00137] [PMID: 25221541]
[12]
Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28(7): 849-57.
[http://dx.doi.org/10.1021/jm00145a002] [PMID: 3892003]
[13]
Mason J, Bortolato A, Weiss D, Deflorian F, Tehan B, Marshall F. High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks. Silico Pharmacol 2013; 1(1): 23.
[http://dx.doi.org/10.1186/2193-9616-1-23]
[14]
Pandey R, Aruna N, Naskar M, et al. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation. J Biomol Struct Dyn 2016.
[http://dx.doi.org/10.1080/07391102.2016.1161560] [PMID: 26984239]
[15]
Huang-Sheng L, Liu H-L, Chen W-H, Yih Ho. Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor. Med Chem Res 2014.
[16]
Sahoo GC, Yousuf Ansari M, Dikhit MR, Kannan M, Rana S, Das P. Structure prediction of gBP21 protein of L. donovani and its molecular interaction. J Biomol Struct Dyn 2014; 32(5): 709-29.
[http://dx.doi.org/10.1080/07391102.2013.789400] [PMID: 23746168]
[17]
Sakkiah SVenkatesh, Arullaperumal Swan Hwang, Keun Woo , Lee . Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors. J Enzyme Inhib Med Chem 2014.
[http://dx.doi.org/10.3109/14756366.2012.753881]
[18]
Sugunadevi S, Chandrasekaran M, Young-Sik S, Sundaraganesan N. Keun Woo Lee. “Identification of Important Chemical Features of 11β-Hydroxysteroid Dehydrogenase Type1 Inhibitors: Application of Ligand Based Virtual Screening and Density Functional Theory. Int J Mol Sci 2012.
[19]
Pavadai E, Hsuan-Liang L, Zhao J, et al. Pharmacophore modeling, virtual screening and docking studies to identify novel HNMT inhibitors Journal of the Taiwan Institute of Chemical Engineers 2012.
[20]
Dhoke GV, Gangwal RP, Sangamwar AT. A combined ligand and structure based approach to design potent PPAR-alpha agonists. J Mol Struct 2012.
[http://dx.doi.org/10.1016/j.molstruc.2012.06.032]
[21]
Bhatt H, Patel P, Pannecouque C. Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation. Chem Biol Drug Des 2014; 83(2): 154-66.
[http://dx.doi.org/10.1111/cbdd.12207] [PMID: 23957390]
[22]
Sakkiah S. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. European Journal of Medicinal Chemistry 2010; 06
[http://dx.doi.org/10.1016/j.ejmech.2010.01.016]
[23]
Cao GP, Arooj M, Thangapandian S, et al. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors. SAR QSAR Environ Res 2015; 26(5): 397-420.
[http://dx.doi.org/10.1080/1062936X.2015.1040453] [PMID: 25986171]
[24]
Shahlaei M, Doosti E. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase. Biomed Pharmacother 2016; 80: 352-72.
[http://dx.doi.org/10.1016/j.biopha.2016.02.041] [PMID: 27133076]
[25]
Sakkiah S. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. European Journal of Medicinal Chemistry 2011; 07
[http://dx.doi.org/10.1016/j.ejmech.2011.04.018]
[26]
Rollinger JM, Stuppner H, Langer T. Virtual screening for the discovery of bioactive natural products. Prog Drug Res 2008; 65: 211-213-249.
[http://dx.doi.org/10.1007/978-3-7643-8117-2_6] [PMID: 18084917]
[27]
Al-Balas Q, Hassan M, Al-Oudat B, Alzoubi H, Mhaidat N, Almaaytah A. Generation of the first structure-based pharmacophore model containing a selective “zinc binding group” feature to identify potential glyoxalase-1 inhibitors. Molecules 2012; 17(12): 13740-58.
[http://dx.doi.org/10.3390/molecules171213740] [PMID: 23174893]
[28]
Niu MM, Qin JY, Tian CP, et al. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking. Acta Pharmacol Sin 2014; 35(7): 967-79.
[http://dx.doi.org/10.1038/aps.2014.34] [PMID: 24909516]
[29]
Ma Y, Li HL, Chen XB, et al. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B. Comput Biol Chem 2018; 73: 1-12.
[http://dx.doi.org/10.1016/j.compbiolchem.2018.01.005] [PMID: 29413811]
[30]
Niu M, Fengzhen W, Li F. Dong Y, Gu Y. Niu M, Fengzhen W, Li F, Dong Y, Gu Y. Establishment of a screening protocol for identification of aminopeptidase N inhibitors. J Taiwan Inst Chem Eng 2015; 49: 19-26.
[31]
Sathishkumar N, Karpagam V, Sathiyamoorthy S, Woo MJ, Kim YJ, Yang DC. Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng. Comput Biol Med 2013; 43(6): 786-97.
[http://dx.doi.org/10.1016/j.compbiomed.2013.02.020] [PMID: 23668355]
[32]
Jain V, Saravanan P, Arvind A, Mohan CG. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening. Chem Biol Drug Des 2011; 77(5): 373-87.
[http://dx.doi.org/10.1111/j.1747-0285.2011.01088.x] [PMID: 21284830]
[33]
Sakkiah S, Thangapandian S, Lee KW. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2. J Mol Model 2012; 18(7): 3267-82.
[http://dx.doi.org/10.1007/s00894-011-1247-5] [PMID: 22249747]
[34]
Raj KK, Ganesh Kumar V, Leela Madhuri C, et al. Designing of potential inhibitors against Staphylococcus aureus sortase A: Combined analogue and structure based approach with in vitro validation. J Mol Graph Model 2015; 60: 89-97.
[http://dx.doi.org/10.1016/j.jmgm.2015.05.009] [PMID: 26119984]
[35]
Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci 2011; 18: 8.
[http://dx.doi.org/10.1186/1423-0127-18-8] [PMID: 21251245]
[36]
Kumar R, Minky S, Rohit Bi. Yuno L. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling. Acta Pharmacol Sin 2015.
[http://dx.doi.org/10.1038/aps.2015.17]
[37]
Maganti L, Grandhi P, Ghoshal N. Integration of ligand and structure based approaches for identification of novel MbtI inhibitors in Mycobacterium tuberculosis and molecular dynamics simulation studies. J Mol Graph Model 2016; 70: 14-22.
[http://dx.doi.org/10.1016/j.jmgm.2016.09.004] [PMID: 27639087]
[38]
Chen X. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors. J Mol Model 2009.
[PMID: 20020310]
[39]
Sakkiah S, Lee KW. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors. Acta Pharmacol Sin 2012; 33(7): 964-78.
[http://dx.doi.org/10.1038/aps.2012.21] [PMID: 22684028]
[40]
Meganathan C. Pharmacophore Design for Anti-Inflammatory Agent Targeting Interleukin-2 Inducible Tyrosine Kinase (Itk). Bull Korean Chem Soc 2010; 31(11): 3333-40.
[http://dx.doi.org/10.5012/bkcs.2010.31.11.3333]
[41]
Singh A, Paliwal S, Sharma M. Sharma S, Tripathi N, Tilak A.. Identification of novel antifungal lead compounds through pharmacophore modeling, virtual screening, molecular docking, antimicrobial evaluation, and gastrointestinal permeation studies. J Biomol Struct Dyn 2017; 35(11): 2363-71.
[http://dx.doi.org/10.1080/07391102.2016.1218369] [PMID: 27464511]
[42]
Huang D, Zhu X, Tang C, et al. 3D QSAR pharmacophore modeling for c-Met kinase inhibitors. Med Chem 2012; 8(6): 1117-25.
[PMID: 22779800] [http://dx.doi.org/10.2174/1573406411208061117]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy